

Lophomonas isolation in sputum sample at Peru

Jeel Moya-Salazar^{1,2}, Richard Salazar-Hernandez³, Madeleine López-Hinostroza⁴, Hans Contreras-Pulache¹

¹School of Medicine, Faculties of Health Science, Norbert Wiener University, Lima, Peru, ²Department of Pathology, Hospital Nacional Docente Madre Niño San Bartolomé, Lima, Peru, ³Department of Pathology, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ⁴Department of Respiratory Disease, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru

ABSTRACT

Lophomonas infection is an emerging parasitic disease causing respiratory infections. After China, Peru is the second country with the highest number of cases. In the bright-field microscopy evaluation of fresh samples, most of them are incorrectly estimated. Therefore, correct identification using cytological stains is to be supplemented. We report a case of a 29-year-old male with typical clinical symptoms of pneumonia, marked eosinophilia, and noninfiltrative pattern in chest X-ray, who had bronchopulmonary lophomoniasis.

KEY WORDS: Emerging disease, *Lophomonas blattarum*, parasite, pulmonary infection

Address for correspondence: Dr. Hans Contreras-Pulache, 440 Arequipa Av. Lima 51001, School of Medicine, Faculties of Health Science, Universidad Norbert Wiener, Lima, Peru. E-mail: hans.contreras@uwiener.edu.pe

Submitted: 26-Aug-2020

Revised: 05-Oct-2020

Accepted: 16-Apr-2021

Published: 03-Jul-2021

INTRODUCTION

Lophomonas is a rising cause of parasitic lung infections in Peru, and Spain.^[1-3] This flagellated protozoan can cause bronchopulmonary lophomoniasis (BPL) with nonspecific symptoms (cough, breathlessness, etc.), eosinophilia, and pulmonary infiltrate.

Lophomonas blattarum and *Lonchura Striata* are the two main species that usually inhabit the intestines of cockroaches, termites, and mites. Therefore, in the environment infested by these insects, the risk of human infection is high, leading to respiratory failure.

Since their identification by Lee and Brugerolle^[4] at the beginning of the millennium, the observation of the morphological characteristics of parasites in biological samples has been conducted by bright-field microscopy

techniques. Since *Lophomonas* cannot be cultured, their microscopic identification is based on the fresh and stained samples evaluation of sputum, bronchoalveolar lavage, and bronchial aspirate. To avoid identification errors, it is recommended to analyze the stained samples, mainly using Papanicolaou (Pap), Giemsa, or trichrome staining.^[5,6]

We report here a clinical case of *Lophomonas* infection in Peru.

CASE REPORT

A 29-year-old male patient arrived at the emergency department with chest pain, a productive cough, fever (approximately 38.5°), and throat inflammation. The processes related to typical pneumonia were ruled step by step: a smear microscopy and sputum culture was performed to search for *Mycobacterium*

Supplementary Video Available on online

Access this article online

Quick Response Code:



Website:

www.lungindia.com

DOI:

10.4103/lungindia.lungindia_696_20

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Moya-Salazar J, Salazar-Hernandez R, López-Hinostroza M, Contreras-Pulache H. *Lophomonas* isolation in sputum sample at Peru. Lung India 2021;38:359-61.

tuberculosis (negative result). Chest X-ray showed a noninfiltrative pattern, sputum cytology was negative for cancer (Pap stain), and the blood count showed eosinophilia (7%). The stool culture and the tests for *Aspergillus fumigatus* were also negative, and the value of C-reactive protein (average: 2.5 mg/L) and the erythrocyte sedimentation (average was 15 mm/h) was elevated. The rest of the clinical examination was unremarkable.

Given the suspicious diagnosis of parasitic disease, fresh sputum sample was sent for microscopic evaluation ($\times 400$ and $\times 1000$), and revealed pear-shaped organisms with linear flagellar movement [Figure 1a and Video Supplementary 1 data]. Pap slides confirmed this finding [Figure 1b], and we also performed Masson's trichome and Giemsa staining to describe in detail the characteristics of the parasites present in the sample [Figures 1c and d].

Paracetamol, cetirizine, and cephalexin were administered for 4 days. Given the cytologic diagnosis, metronidazole was used for a week. The clinical manifestations improved rapidly 2 to 3 weeks after starting of antiparasitic treatment, with complete resolution at 5 weeks.

DISCUSSION

Although this finding establishes a link between *Lophomoniasis* causing-respiratory disease, its scrutiny is misestimated on a daily workflow. Therefore, lung infection is rejected as the cause of respiratory disease. Although advances in molecular techniques^[7] may reduce these problems, they are still challenges in identifying BPL.

The fresh observation of this flagellated parasite measuring $60 \times 20 \mu$ can be confused with ciliated cells or may be unnoticed in its evaluation. For this reason, the use of stained smears is suggested for the microscopic evaluation of its characteristics. This study also demonstrated the

usefulness of other staining techniques that allow us to observe this protozoan present in samples from patients with respiratory disease.

BLP has been reported in patients with some degree of immunosuppression such as with hematopoietic transplantation^[8] or leukemia,^[9] in patients with sinusitis,^[10] asthma,^[11] tuberculosis,^[12] and also in the immunocompetent population.^[13] In this case, the clinical manifestations of BPL in an immunocompetent patient have significant eosinophilia consistent with previous reports.^[3]

To date, several studies have focused on *L. blattarum* infection, and rare cases of BPL are becoming more frequent. In the case of Peru, which has about 10% of case reports, the northern populations are more affected, of reported cases, the northern populations are the most affected, with patients from the Intensive Care Units being the most affected.^[14,15] Further studies are required to understand whether *L. blattarum* is endemic.

Finally, the case report and documentation of the parasite are essential for understanding the pathophysiological processes of its human infection, improving diagnostic methods, and promoting preventive measures against the parasite that causes BPL.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his images and other clinical information to be reported in the journal. The patient understands that his name and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. He Q, Chen X, Lin B, Qu L, Wu J, Chen J. Late onset pulmonary *Lophomonas blattarum* infection in renal transplantation: A report of two cases. *Intern Med* 2011;50:1039-43.
2. Zerpa R, Ore E, Patiño L, Espinoza YA. *Lophomonas* sp. in respiratory tract secretions in hospitalized children with severe lung disease. *Rev Peru Med Exp Salud Publica* 2010;27:575-7.
3. Berenji F, Fata A, Vakili V, Sayedi SJ, Bahared A, Hajar I, et al. Unexpected high rate of *Lophomonas blattarum* in resistant upper and lower respiratory infection. *Int J Med Res Health Sci* 2016;5:74-80.
4. Brugerolle G, Lee JJ. Phylum parabasalida. In: Lee JJ, Leedale GF, editors. *An Illustrated Guide to the Protozoa*. 2nd ed. Philadelphia: Society of Protozoologists; 2000.
5. Martínez-Girón R, van Woerden HC, Doganci L. *Lophomonas* misidentification in bronchoalveolar lavages. *Intern Med* 2011;50:2721.
6. Alam-Eldin YH, Abdulaziz AM. Identification criteria of the rare multi-flagellate *Lophomonas blattarum*: Comparison of different staining techniques. *Parasitol Res* 2015;114:3309-14.




Figure 1: *Lophomonas* in sputum sample. (a) Fresh sample. (b) Papanicolaou stain. (c) Giemsa stain. (d) Masson's trichome stain

7. Fakhar M, Nakhaei M, Sharifpour A, Kalani H, Banimostafavi ES, Abedi S, et al. First molecular diagnosis of lophomoniasis: The end of a controversial story. *Acta Parasitol* 2019;64:390-3.
8. González SN, Otero MF, Rivas LF, Galvis TD, Venegas ME, Arias DE, et al. Bronchopulmonary infection by *Lophomonas blattarum* in a pediatric patient after hematopoietic progenitor cell transplantation: First report in Mexico. *J Thorac Dis* 2017;9:E899-902.
9. Vidal C, Barthel E, Rodríguez MA. Lung infection by *Lophomonas* spp. in a female patient with acute myeloid leukemia. *Rev Per Med Exp Salud Publica* 2018;35:527-30.
10. Berenji F, Parian M, Fata A, Bakhshae M, Fattahi F. First case report of sinusitis with *Lophomonas blattarum* from Iran. *Case Rep Infect Dis* 2016;2016:2614187.
11. Yao GZ, Zeng LQ, Zhang B, Chang ZS. Bronchopulmonary *Lophomonas blattarum* infection: Two cases report and literature review. *Zhonghua Nei Ke Za Zhi* 2008;47:634-7.
12. Verma S, Verma G, Singh DV, Mokta J, Negi RS, Jhobta A, et al. Dual infection with pulmonary tuberculosis and *Lophomonas blattarum* in India. *Int J Tuberc Lung Dis* 2015;19:368-9.
13. Tyagi R, Anand KB, Teple K, Negi RS. *Lophomonas blattarum* infection in immunocompetent patient. *Lung India* 2016;33:667-8.
14. Rodríguez VJ, Díaz SR, Pérez MP, Lora LMG. *Lophomonas*: A probable emerging zoonosis in critical services of a hospital in the Lambayeque region. *Rev Epistemia* 2020;4.
15. Iglesias-Osores S, Acosta-Quiroz J. *Lophomonas* sp. respiratory pathogen and possible indicator of hospital contamination? *Rev Chil Enferm Respir* 2020;36:62-4..